Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide

Pamela Thompson; Vani Lakshminarayanan; Nitin T. Supekar; Judy M. Bradley; Peter A. Cohen; Margreet A. Wolfert; Sandra J. Gendler; Geert Jan Boons

doi:10.1039/c5cc02199e

Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide

Pamela Thompson, Vani Lakshminarayanan, Nitin T. Supekar, Judy M. Bradley, Peter A. Cohen, Margreet A. Wolfert, Sandra J. Gendler, Geert Jan Boons^*

^*Corresponding author for this work

Chemical Biology and Drug Discovery

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

A strategy for the linear synthesis of a sialylated glycolipopeptide cancer vaccine candidate has been developed using a strategically designed sialyl-Tn building block and microwave-assisted solid-phase peptide synthesis. The glycolipopeptide elicited potent humoral and cellular immune responses. T-cells primed by such a vaccine candidate could be restimulated by tumor-associated MUC1.

Original language	English
Pages (from-to)	10214-10217
Number of pages	4
Journal	Chemical Communications
Volume	51
Issue number	50
DOIs	https://doi.org/10.1039/c5cc02199e
Publication status	Published - 28 May 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1039/c5cc02199e

c5cc02199eFinal published version, 1.51 MBLicence: Taverne

Cite this

@article{beb7701cb22d4e928ae28ea4e9cb3b91,

title = "Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide",

abstract = "A strategy for the linear synthesis of a sialylated glycolipopeptide cancer vaccine candidate has been developed using a strategically designed sialyl-Tn building block and microwave-assisted solid-phase peptide synthesis. The glycolipopeptide elicited potent humoral and cellular immune responses. T-cells primed by such a vaccine candidate could be restimulated by tumor-associated MUC1.",

author = "Pamela Thompson and Vani Lakshminarayanan and Supekar, {Nitin T.} and Bradley, {Judy M.} and Cohen, {Peter A.} and Wolfert, {Margreet A.} and Gendler, {Sandra J.} and Boons, {Geert Jan}",

year = "2015",

month = may,

day = "28",

doi = "10.1039/c5cc02199e",

language = "English",

volume = "51",

pages = "10214--10217",

journal = "Chemical Communications",

issn = "1359-7345",

publisher = "Royal Society of Chemistry",

number = "50",

}

TY - JOUR

T1 - Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide

AU - Thompson, Pamela

AU - Lakshminarayanan, Vani

AU - Supekar, Nitin T.

AU - Bradley, Judy M.

AU - Cohen, Peter A.

AU - Wolfert, Margreet A.

AU - Gendler, Sandra J.

AU - Boons, Geert Jan

PY - 2015/5/28

Y1 - 2015/5/28

N2 - A strategy for the linear synthesis of a sialylated glycolipopeptide cancer vaccine candidate has been developed using a strategically designed sialyl-Tn building block and microwave-assisted solid-phase peptide synthesis. The glycolipopeptide elicited potent humoral and cellular immune responses. T-cells primed by such a vaccine candidate could be restimulated by tumor-associated MUC1.

AB - A strategy for the linear synthesis of a sialylated glycolipopeptide cancer vaccine candidate has been developed using a strategically designed sialyl-Tn building block and microwave-assisted solid-phase peptide synthesis. The glycolipopeptide elicited potent humoral and cellular immune responses. T-cells primed by such a vaccine candidate could be restimulated by tumor-associated MUC1.

UR - http://www.scopus.com/inward/record.url?scp=84931282137&partnerID=8YFLogxK

U2 - 10.1039/c5cc02199e

DO - 10.1039/c5cc02199e

M3 - Article

AN - SCOPUS:84931282137

SN - 1359-7345

VL - 51

SP - 10214

EP - 10217

JO - Chemical Communications

JF - Chemical Communications

IS - 50

ER -

Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this